With the mutated coronavirus being detected in a number of countries, Wafaa El-Sadr, MD, MPH, MPA, global director of ICAP, urges for continued testing. “There’s a need for the laboratory infrastructure to be there to be doing this kind of work, because it will shed light in terms of where are new variants arising, what’s dominating in the community, where are transmissions,” she said.
A major global health organization that has been improving public health in countries around the world for over 15 years, ICAP works to transform the health of populations through innovation, science, and global collaboration. Based at Columbia University in New York City, where it is part of the Mailman School of Public Health, ICAP has projects in more than 30 countries, working side-by-side with ministries of health and local partners to confront some of the world’s toughest health challenges. Through meaningful research, tailored technical assistance, effective training and education programs, and rigorous surveillance to measure and evaluate the impact of public health interventions, ICAP aims to realize a global vision of healthy people, empowered communities, and thriving societies. Online at icap.columbia.edu